• Curriculum Vitae
  • Teaching
  • Appointments
  • Research

Date of birth: 06/10/1975
Place of birth: Asola (MN),
Home address: strada Cinghio 32, 43124 Parma (PR)
Home telephone: 05211859970; Mobile: 3346063163
Work address: Dipartimento di Scienze degli Alimenti e del Farmaco, Università di Parma
Parco Area delle Scienze 27/A
43124 Parma
Work telephone: 0521/905040
E-mail: ilaria.zanotti@unipr.it

EDUCATION
2000 Graduated in Pharmaceutical Chemistry and Technology (110/110).

2005 PhD in Experimental Pharmacology and Toxicology

2007 Assistant Professor of Pharmacology at the University of Parma
2017 Qualified as Associate Professor of Pharmacology, Clinical Pharmacology and Pharmacognosy (Academic recruitment field 05/G1) at the Call 1532/2016

WORK EXPERIENCE

2000 Fellowship from the V Framework Programme (Project QLG1-1999-01007) (1 year)

2002 Visiting scientist for 12 months at the Children’s Hospital of Philadelphia (USA), working in the Lipid Research Group (Responsible Prof. George H. Rothblat)

2004 Fellowship from the FIRB project (Project RBNE01BNFK-003) (1 year).

2005-2007 Fellowship from Istituto Nazionale per le Ricerche Cardiovascolari (18 months)

2008 Post doc fellowship from the Società Italiana di Farmacologia (4 months)

AWARDS
2000 Grant from the Nutrition Foundation of Italy
2004 Grant from AstraZeneca for the best oral presentation at the XVIII National Congress of the Italian Society of Atherosclerosis (SISA) (Palermo).
2006 Travel award for the participation at the XIV International Symposium on Atherosclerosis (Roma).
2007 Young Investigator Award at the IAS Sponsored Workshop on HDL (Santorini, Grecia)
2009 Travel awards for the participation at the XXIII National Congress of the Italian Society of Atherosclerosis (SISA) (Roma).
Grant from AstraZeneca for the best oral presentation at the XXIII National Congress of the Italian Society of Atherosclerosis (SISA) (Roma).
2010 Travel grant for the participation at the XXIV National Congress of the Italian Society of Atherosclerosis (SISA) (Roma).
2012 Travel grant for the participation at the XXVI National Congress of the Italian Society of Atherosclerosis (SISA) (Roma).

SCIENTIFIC SOCIETIES
- Società Italiana per lo Studio dell’Arteriosclerosi
- Società Italiana per le Ricerche Cardiovascolari
- Società Italiana di Farmacologia
- International Society of Arteriosclerosis
- European Lipoprotein Club

PARTICIPATION AT FUNDED PRIVATE AND PUBLIC PROJECTS
2000 V Framework Programme 1999 Project QLG1-1999-01007
"Macrophage function and stability of the atherosclerotic plaque" (MAFAPS). (Component of the research group)

PRIN-Cofin
“Deficit familiari delle lipoproteine ad alta densità. Aspetti genetici, biochimici e clinici”. (High density lipoprotein familial deficiency. Genetic, biochemical and clinical aspects) (Component of the research group)

Grant from RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A., Milano (Italia)
"Study on the potential antiatherosclerotic activity of the association lercanidipine and statins: effect on lipid metabolism and matrix metalloproteinase secretion in murine and human macrophages in culture”. (Component of the research group)

2001 FIRB
“Nuove strategie per la prevenzione ed il controllo dell’ischemia cerebrale su base vascolare: ruolo dei meccanismi infiammatori e proteolitici”. (New strategies for the prevention and the management of cerebral ischemia: role of inflammatory and proteolytic mechanisms) (Component of the research group)

2002 Grant from SIGMA-TAU, Pomezia (Italia)
“Effetto del Losartan e dell’Acido Urico sui Meccanismi cellulari dell’aterogenesi”. (Losartan and Uric Acid effect on the cellular mechanisms of atherogenesis) (Component of the research group)

Grant from FOURNIER PHARMA, Segrate (Italia)
“Effetto dei fibrati sul potenziale di efflusso del colesterolo di soggetti trattati” (Fibrate effect on plasma efflux potential) (Component of the research group)

Grant from GSK-GLAXO SMITH KLINE, Verona (Italia)
“Studies on compound GW597599b: effect on intracellular lipid metabolism”. (Component of the research group)

2003 Grant from KOWA COMPANY S.p.A., Tokyo (Japan)
“Study on the effect of pitavastatin on cellular cholesterol trafficking and cholesterol induced cytotoxicity”. (Component of the research group)

Grant from RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A., Milano (Italia)
“Study on the effect of lercanidipine on cellular cholesterol trafficking and cholesterol induced cytotoxicity”. (Component of the research group)

2004 Grant from ASTRAZENECA, Basiglio (Italia)
“Study on the mechanisms of antiatherosclerotic effects of rosuvastatin: focus on reverse cholesterol transport in in vivo and in vitro models”. (Component of the research group)

Grant from SIENABIOTECH, Siena (Italia)
“Definizione di LXR/FXR quali target farmacologici e sviluppo di molecole agoniste con potenziale attività protettiva sulla patologia di Alzheimer” (LXR/FXR as pharmacological targets for the development of agonists with potential beneficial effects towards Alzheimer disease” (Component of the research group)

2005 PRIN
“Fisiopatologia delle lipoproteine plasmatiche ad alta densità (HDL): un approccio integrato”. (Physiopathology of high density lipoproteins: an integrated approach) (Component of the research group)

2006 Grant from KOWA COMPANY S.p.A., Tokyo (Japan)
“Modulation of cholesterol efflux by pitavastatin: in vitro studies". (Component of the research group)

Grant from CIRCOMED AG, (Basel, Switzerland)
“Study on the modulation of reverse cholesterol transport by RO 11-1464 through a novel experimental approach”. (Co-Responsible of the project)

2007 Grant from Merck Sharp & Dohme (Roma, Italia)
“Study on nicotinic acid effect on lipid metabolism in cultured macrophages” (Co-Responsible of the project)

2009 Grant from Chiesi Farmaceutici (Parma, Italia)
“Studio in vivo dell’effetto anti-aterosclerotico-anti-infiammatorio della manidipina e dell’associazione manidipina/delapril in modelli sperimentali di topo obeso e di topo diabetico” (Component of the research group)

2010 Grant from Merck Sharp & Dohme (Roma, Italia)
“Study on the impact of nicotinic acid treatment “in vivo” on macrophage reverse cholesterol transport (Co-Responsible of the project)

2012 Cariplo Foundation
“Investigating the role of pro-protein convertase subtilisin/kexin type 9 (PCSK9) released from smooth muscle cells on atherogenesis” (Component of the research group)

2013 Grant from The Medicines Company (Parsippany, NJ, USA)
Effect of MDCO-216 on the Secretion of APOE by Macrophages (Responsible of the project)

2014 Grant from the European Foundation for Alcohol Research (Louvain La Neuve, Belgium)
Impact of alcohol consumption on the atheroprotective process of the reverse cholesterol transport (Responsible of the project)

Ricerca finalizzata del Ministero della Salute
Targeting inflammation in atherosclerosis: role and therapeutic potential of sphingosine 1-
phosphate (S1P) and its receptors (Responsible of a research unit)

Grant from the National Processed Raspberry Council
The protective effects of raspberry polyphenol metabolites part II: neurodegeneration, reverse cholesterol transport and endothelial dysfunction and haemostasis (Responsible of a research unit)

Grant from Rottapharm (Monza, Italia)
Effetti in vivo di lievito rosso, policosanoli e berberina sul processo antiaterogeno di trasporto inverso del colesterolo e infiammazione sistemica (Component of the Research group)
2017 Grant from Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Role of gut microbiota in calcific aortic valve stenosis pathogenesis (Component of the Research group)

TEACHING ACTIVITY
A.A. 2007/2008- 2008/2009- 2009/2010- 2010/2011
Preclinical Studies of the Biotechnological Drugs (1 CFU) for the Course of Medical, Veterinary and Pharmaceutical Biotechnologies.
A.A. 2008/2009
Pharmacognosy (4 CFU) for Herbal Science and Health Products
A.A. 2009/2010- 2010/2011-2011/2012- 2012/2013-2013/2014
Pharmacognosy (5 CFU) for Pharmaceutical Chemistry and Technology

Dr Zanotti is taking care of several students during their experimental thesis since A.A. 2003-2004. In detail, she was supervisor of 5 students of Medical, Veterinary and Pharmaceutical Biotechnologies, 6 students Pharmaceutical Chemistry and Technology and 7 students of Herbal Science and Health Products.
Starting from January 2017 Dr Zanotti participates at the Committee for International Mobility of the Department of Food and Drug.

Starting from September 2016 Dr Zanotti is the Secretary of the Consiglio Direttivo della Società Italiana per lo Studio dell’Arteriosclerosi, sezione Emilia Romagna.

EXPERTISE
In vitro and in vivo models to study pathogenesis and pharmacological modulation of atherosclerosis.

Cell cultures: human monocytes and macrophages (primary and tumoral), human skin fibroblasts, murine macrophages (P388, J774, RAW264.7, primary peritoneal, bone marrow-derived), rodent hepatic cells (Fu5AH, HepG2), human endothelial cells (HUVECs), human intestinal cells (Caco-2), human neuronal cells (Neuro2a, IMR32).

Lipoproteins: modifications: acetylation and oxidation

In vitro cell lipid homeostasis through radioisotopic techniques:
• Cholesterol synthesis
• Cholesterol esterification
• Cholesterol hydrolisis
• Cholesterol enrichment of the membrane
• Cholesterol efflux
• Phospholipid efflux
• Cholesterol-dependent citotoxicity
In vitro cell lipid homeostasis through fluorimetric techniques:
Cholesterol uptake

Inflammatory functions of macrophages
• NO secretion (colorimetric technique)
• Cytokine secretion (ELISA)
• Adhesion to extracellular matrix (colorimetric technique)
• Adhesion to HUVECs (fluorimetric technique)
• Cell migration (Boyden chamber technique)

Molecular biology: western blot, PCR, RT-PCR, ELISA.
Animals: mice.
In vivo quantification of the reverse cholesterol transport (radioisotopic technique)
The principal areas of studies include:
• Role of apolipoprotein E in lipid homeostasis and atherogenesis
• Role of sphingosin 1 phosphate and PCSK9 in lipid homeostasis and atherogenesis
• Eph/ephrin as target for antiatherosclerotic drugs
• Nutraceutical (alcohol, polyphenols, probiotics) modulation of cell lipid homeostasis and reverse cholesterol transport
• Pharmacological modulation of cell lipid homeostasis and reverse cholesterol transport

FOREIGN LANGUAGES
Basic knowledge of French.
Good knowledge of English.

INFORMATICS
Microsoft Word, Microsoft Excel, Microsoft Power Point, GraphPrisma, Photoshop, EndNote.

CONGRESSES
Oral presentations
2000 XIV CONGRESSO NAZIONALE DELLA SOCIETÀ ITALIANA PER LO STUDIO DELL'ARTERIOSCLEROSI (S.I.S.A.), Perugia
Effetto del Carvedilolo sull'esterificazione del colesterolo e sulla secrezione di ossido d'azoto in macrofagi in coltura
Zanotti, E. Favari, M. Canavesi, S. Bellosta, F. Bernini.

2003 31° CONGRESSO NAZIONALE DELLA SOCIETÀ ITALIANA DI FARMACOLOGIA, Trieste
Probucol inhibition of ABCA1-mediated cellular lipid efflux
Bernini F., Favari E., Zanotti I., Zimetti F., Ronda N., Rothblat G.H.

26th ANNUAL MEETING OF THE LIPOPROTEIN CLUB, Tutzing
Effect of ApoA-I on “in vivo” reverse cholesterol transport from macrophages
Ilaria Zanotti, YuZhen Zhang, Muredach Reilly, Jane M. Glick, George H. Rothblat, Daniel J. Rader.

2004 L’EPIDEMIOLOGIA E LA PREVENZIONE DELLE MALATTIE CARDIOVASCOLARI: DAL PIONIERISMO ALL’EVIDENZA SCIENTIFICA. Giancarlo Descovich: l’opera e la scuola, Bologna
Effect of apoA-I overexpression on “in vivo” reverse cholesterol transport from macrophages
Ilaria Zanotti, Yuzhen Zhang, Muredach Reilly, Jane M. Glick, George H. Rothblat, Daniel J. Rader.

XI CONGRESSO NAZIONALE DELLA SOCIETÀ ITALIANA DI RICERCE CARDIOVASCOLARI, Latina
Effetto delle statine sull’efflusso ABCA1 in macrofagi e cellule epatiche
I. Zanotti, E. Favari, M.P. Adorni, F. Zimetti, F. Bernini.

XV INTERNATIONAL SYMPOSIUM ON DRUGS AFFECTING LIPID METABOLISM, Venezia
Dual effect of statins on ABCA1-mediated lipid efflux from macrophages and hepatic cells
I. Zanotti, E. Favari, M.P. Adorni, F. Zimetti, F. Bernini

XVIII CONGRESSO NAZIONALE SISA, ARTERIOSCLEROSI E MALATTIE CARDIOVASCOLARI: DALLA SCIENZA DI BASE ALLA CLINICA, Palermo
Effetto delle statine sull’efflusso ABCA1 in macrofagi e cellule epatiche
Zanotti, E. Favari, M.P. Adorni, F. Zimetti, F. Bernini.

2005 75th EAS CONGRESS, Praga
Pitavastatin differently modulates ABCA1-mediated lipid efflux in macrophages and hepatic cells
Zanotti, E. Favari, MP. Adorni, F. Zimetti, F Bernini.

2006 XIV INTERNATIONAL SYMPOSIUM ON ATHEROSCLEROSIS, Roma
Effect of the LXR agonist T0901317 on reverse cholesterol transport in vivo
Ilaria Zanotti, Francesco Potì, Elda Favari, Stefano Bellosta, Franco Bernini

XIII CONGRESSO NAZIONALE DELLA SOCIETÀ ITALIANA DI RICERCHE CARDIOVASCOLARI, Imola
Meccanismo di attivazione dell’ATP-bindng cassette A1 da parte del cAMP
I. Zanotti, F. Potì, E. Favari, K.B. Steffensen, J.Å. Gustafsson, F. Bernini

XX CONGRESSO NAZIONALE SISA, Bologna
The LXR agonist T0901317 increases the efflux potential of sera and promotes the reverse cholesterol transport in mice
I. Zanotti, F. Potì, M. Pedrelli, E. Favari, L. Calabresi, E. Moleri, F. Bernini

2007 II Workshop on Lipid Metabolism and Vascular Biology, Parma
Pharmacological modulation of in vivo reverse cholesterol transport
I. Zanotti

VII CONVEGNO REGIONALE SISA SEZIONE REGIONALE EMILIA ROMAGNA, Parma
La rosuvastatina promuove il trasporto inverso del colesterolo nei topi
I. Zanotti, F. Potì, M.Pedrelli, E.Favari, F. Bernini

2009 X CONVEGNO REGIONALE SISA SEZIONE REGIONALE EMILIA ROMAGNA, Ferrara
Trasporto inverso del colesterolo: fattori determinanti l’efficienza del processo
I. Zanotti, G. Stomeo, F. Potì, M. Pedrelli, F. Zimetti, F. Bernini

XXIII CONGRESSO NAZIONALE SISA, Roma
Cyclosporine a modulates the macrophage reverse cholesterol transport in vivo
I. Zanotti, G. Stomeo, F. Zimetti, F. Potì, F. Bernini

2010 III Workshop on Lipid Metabolism and Vascular Biology, Stoccolma
New insights into the regulation of the reverse cholesterol transport in vivo

XXIV CONGRESSO NAZIONALE SISA, 24-27 novembre 2010, Roma
Macrophage, but not systemic, apolipoprotein E is necessary for macrophage reverse cholesterol transport in vivo
I.Zanotti, G. Stomeo, F. Zimetti, F. Potì, F. Bernini

2012 CONVEGNO MONOTEMATICO DELLA SIF: NUOVE FRONTIERE NELLA TERAPIA DELL’ATEROSCLEROSI, 3 febbraio 2012, Milano
La Ciclosporina A Riduce il Trasporto Inverso del Colesterolo nei Topi Attraverso l’inibizione dell’Escrezione Fecale
I.Zanotti I, G. Lusardi, D. Greco, F. Potì, F.Bernini

80th EAS Congress Satellite Symposium: High Density Lipoproteins, from basic science to therapeutic advances, 28-29 maggio 2012, Milano
CyclosporineA Impairs the Reverse Cholesterol Transport from Macrophages in vivo by Reducing Sterol Fecal Excretion
I.Zanotti I, G. Lusardi, D. Greco, F. Potì, F.Bernini

1st SIRC Workshop on “New Roads in Cardiovascular Research”
Milano 23-24 novembre 2012
The immunosuppressant drug cyclosporine A impairs the reverse cholesterol transport in vivo by reducing sterol fecal excretion
I.Zanotti I, G. Lusardi, D. Greco, F. Potì, F.Bernini

2013 XIX Congresso Nazionale della Società Italiana di Ricerche Cardiovascolari
Imola, 17 - 19 ottobre 2013
Studio Dell’attività In Vivo Di Un Nuovo Inibitore Della Lecitina Colesterolo Aciltransferasi
I. Zanotti, S. Simonelli, I. Eberini, C.Sensi, G. Lusardi, G. Franceschini, F. Bernini, L. Calabresi

36° CONGRESSO NAZIONALE DELLA SOCIETÀ ITALIANA DI FARMACOLOGIA, Torino, 23-26 ottobre 2013
Characterization of in vivo activity of a novel Lecithin:cholesterol acyltransferase inhibitor
I. Zanotti, S. Simonelli, I. Eberini, C.Sensi, G. Lusardi, G. Franceschini, F. Bernini, L. Calabresi

2014 XXVIII CONGRESSO NAZIONALE SISA, 23-25 novembre 2014, Roma
Investigating the hypocholesterolemic activity of bifidobacterium bifidum PRL2010: in vitro and in vivo approaches
I. Zanotti, A. Piemontese, F. Turroni, L. Elviri, F. Bernini, M. Ventura

2015 37° CONGRESSO NAZIONALE DELLA SOCIETÀ ITALIANA DI FARMACOLOGIA, Napoli, 27-30 ottobre 2015
Opposite effects of moderate and excess alcohol consumption on the atheroprotective process of the reverse cholesterol transport in vivo
I. Zanotti, D. Greco, L. Mele, A. Piemontese, S. Battista, A. Poli, F. Bernini
2016 XXX CONGRESSO NAZIONALE SISA, 20-22 novembre 2014, Roma
Ruolo della sfingosina 1-fosfato e del suo recettore S1P3 nel trasporto inverso del colesterolo
I. Zanotti, D. Greco, S. Battista, L.B. Giva, M.P. Adorni, G.D. Norata, M. Simoni, F. Bernini, J.R. Nofer, F. Potì

Poster presentations
2001 30° CONGRESSO NAZIONALE DELLA SOCIETÀ ITALIANA DI FARMACOLOGIA, Genova
Effect of carvedilol on cholesterol esterification and nitric oxide synthesis in cultured macrophages
I. Zanotti, N. Baldini, E. Favari, S. Bellosta, F. Bernini.

XIV INTERNATIONAL SYMPOSIUM ON DRUGS AFFECTING LIPID METABOLISM, New York
Effect of carvedilol on cholesterol esterification and nitric oxide synthesis in cultured macrophages
Zanotti, M. Canavesi, N. Baldini, E. Favari, S. Bellosta, F. Bernini

2003 X CONGRESSO NAZIONALE DELLA SOCIETÀ ITALIANA DI RICERCHE CARDIOVASCOLARI, Roma
Effetto del carvedilolo sul metabolismo del colesterolo nei macrofagi
Zanotti I., Favari E., Baldini N., Visioli O., Bernini F.

XVII CONGRESSO NAZIONALE SISA, Nutrizione, Metabolismo e Aterosclerosi, Napoli
Effect of apoA-I overexpression on “in vivo” reverse cholesterol transport from macrophages
Ilaria Zanotti, YuZhen Zhang, Muredach Reilly, Jane M. Glick, George H. Rothblat, Daniel J. Rader.

2004 74th EAS CONGRESS, Seville
Fu5AH express functional ABCA1 upon treatment with 22OH-cholesterol and cis-9 retinoic acid
Zanotti I, Favari E, Rothblat G, Bernini F.

Analysis of lipid efflux in fibroblasts from Niemann Pick Type C disease subjects
Ilaria Zanotti, Sebastiano Calandra, Patrizia Tarugi, Franco Bernini.

5th ANNUAL CONFERENCE ON ARTERIOSCLEROSIS,THROMBOSIS AND VASCULAR BIOLOGY, San Francisco
Fu5AH express functional ABCA1 upon treatment with 22OH-cholesterol and cis-9 retinoic acid
Ilaria Zanotti, Elda Favari, George H. Rothblat, Franco Bernini.

2004 HDL WORKSHOP, Heraklion
Dual effect of statins on ABCA1-mediated lipid efflux from macrophages and hepatic cells
I. Zanotti, E. Favari, M.P. adorni, F. Zimetti, F. Bernini.

27th ANNUAL MEETING OF THE LIPOPROTEIN CLUB, Tutzing
Expression of functional ABCA1 in Fu5AH rat hepatoma cells
Ilaria Zanotti, Elda Favari, George H. Rothblat, Franco Bernini

2006 29th ANNUAL MEETING OF THE LIPOPROTEIN CLUB, Tutzing
The contribution of different mechanisms of efflux in fibroblasts
M. Duong, H.L. Collins, W. Jin, I. Zanotti, E. Favari, G.H. Rothblat

The in vivo stimulation of LXR promotes the reverse cholesterol transport in vivo by increasing the efflux potential of sera
I. Zanotti, F. Potì, M. Pedrelli, E. Favari, S. Bellosta*, F. Bernini

Modulation of cholesterol efflux in human THP-1 monocytes-derived macrophages
E. Favari, I. Zanotti, M.P. Adorni, G.H. Rothblat, F. Bernini

2007 IAS-SPONSORED WORKSHOP ON HDL: STRUCTURE, PROTECTIVE FUNCTIONS AND THERAPEUTIC APPLICATIONS, Santorini
RO11-1464 promotes faecal sterol excretion in apoA-I overexpressing mice
Zanotti I, Pedrelli M, Zambelli E, Kempen H, Bernini F

33° CONGRESSO NAZIONALE DELLA SOCIETÀ ITALIANA DI FARMACOLOGIA, Cagliari
In vivo stimulation of LXR increases the efflux potential of sera and promotes the reverse cholesterol transport
Zanotti Ilaria, Potì Francesco, Pedrelli Matteo, Favari Elda, Calabresi Laura,Moleri Elsa, Bernini Franco

XXI CONGRESSO NAZIONALE SISA, Perugia
The benzodiazepine analogue CIM2-LC alters plasma lipid profile and promotes faecal sterol excretion in apoA-I overexpressing mice.

Zanotti Ilaria, Pedrelli Matteo, Zambelli Enrico, Favari Elda, Calabresi Laura, Franceschini Guido, Kempen Herman, Bernini Franco

2009 XV INTERNATIONAL SYMPOSIUM ON ATHEROSCLEROSIS, Boston (USA)
Role of apolipoprotein E in the reverse cholesterol transport in vivo
Ilaria Zanotti, Francesco Potì, Matteo Pedrelli, Grazia Stomeo and Franco Bernini

2010 33rd European Lipoprotein Club meeting, Tutzing
Cyclosporine a affects the reverse cholesterol transport from macrophages in vivo
I. Zanotti, G. Stomeo, F. Zimetti, F. Bernini

2012 80th EAS Congress, 25-28 maggio 2012, Milano
A short term administration of CyclosporineA Impairs the Reverse Cholesterol Transport from Macrophages in vivo
I.Zanotti, G. Lusardi, D. Greco, F. Potì, F.Bernini

XXVI CONGRESSO NAZIONALE SISA, Roma
The immunosuppressive drug cyclosporine A impairs the reverse cholesterol transport in vivo by reducing sterol fecal excretion
I.Zanotti I, G. Lusardi, D. Greco, F. Potì, F.Bernini

35th European Lipoprotein Club meeting
Cyclosporine A Impairs The Reverse Cholesterol Transport From Macrophages In Vivo By Reducing Sterol Fecal Excretion
I.Zanotti, G. Lusardi, D. Greco, F. Potì, F.Bernini

2014 82th EAS Congress, 31 maggio-3 giugno, Madrid (Spagna)
Evaluation of antiatherosclerotic effects of ellagic acid metabolites in cultured macrophages
Zanotti I, Piemontese A, Bernini F, Del Rio D

2015 INTERNATIONAL SYMPOSIUM ON ATHEROSCLEROSIS 2015 24-26 May, Amsterdam
Dietary Ellagitannin Metabolites Exert Antiatherosclerotic Effects in Vitro
Ilaria Zanotti, Laura Mele, Valentina Marino, Antonio Piemontese, Franco Bernini, Daniele Del Rio

38th European Lipoprotein Club meeting
Cholesterol efflux capacity, HDL-c levels and coronary calcium score among the very elderly subjects
Francesca Zimetti, Ilaria Zanotti, Elda Favari, Franco Bernini, Luiz A. Quaglia, Alessandra M. Campos, Wladimir M. Freitas and Andrei C. Sposito
2017 85th EAS Congress, 23-26 aprile, Praga (Repubblica Ceca)
Trimethylamine-N-Oxide Promotes The In Vitro Formation Of Macrophage Foam Cells
L. Mele, A. Adamo, R. De Francesco, G. Aragones, D. Del Rio, F. Bernini, I. Zanotti

Invited lectures
2010 Congresso SID-AMD Regione Emilia Romagna
Approccio nutraceutico al rischio residuo

2012 Scuola di Nutrizione ed Integrazione nello Sport
Elementi di integrazione alimentare: Nutraceutici, fitocomplessi, bioflavonoidi e omega 3

XII SIMPOSIO DELLA SEZIONE REGIONALE EMILIA ROMAGNA DELLA SISA
Meccanismi di regolazione del trasporto inverso del colesterolo

2015 XV SIMPOSIO DELLA SEZIONE REGIONALE EMILIA ROMAGNA DELLA SISA
Microbiota ed aterosclerosi

PUBLISHED MANUSCRIPTS
1. Altilia S, Pisciotta L, Garuti R, Tarugi P, Cantafora A, Calabresi L, Tagliabue J, Maccari S, Bernini F, Zanotti I, Vergani C, Bertolini S, Calandra S “Abnormal splicing of ABCA1pre-mRNA in Tangier disease due to an IVS2+5G>C mutation in ABCA1 gene” Journal of Lipid Research 2003; 44: 254-264. Impact factor: 3,893.

2. YuZhen Zhang*, Ilaria Zanotti*, Muredach Reilly, Jane M. Glick, George H. Rothblat, Daniel J. Rader “Overexpression of apoA-I promotes reverse transport of cholesterol from macrophages to feces in vivo” Circulation 2003; 108(6): 661-663. Impact factor: 11,164.
*I due autori hanno contribuito in maniera equivalente al lavoro

3. Ilaria Zanotti, Elda Favari, Andrei C. Sposito, George H. Rothblat, and Franco Bernini “Pitavastatin increases ABCA1-mediated lipid efflux from Fu5AH rat hepatoma cells” Biochemical and Biophysical Research Communications 321 (2004) 670-674. Impact factor: 2,904.

4. Elda Favari, Ilaria Zanotti, Francesca Zimetti, Nicoletta Ronda, Franco Bernini and George H. Rothblat “Probucol inhibits ABCA1-mediated cellular lipids efflux“. Arteriosclerosis, Thrombosis and Vascular Biology (2004) 24(12):2345-50. Impact factor: 7,432.

5. Favari E, Zimetti F, Bortnick AE, Adorni MP, Zanotti I, Canavesi M, Bernini F. “Impaired ATP-binding cassette transporter A1-mediated sterol efflux from oxidized LDL-loaded macrophages”. FEBS Lett. 2005;579(29):6537-42. Impact factor: 3,415

6. Zanotti I, Poti F, Favari E, Steffensen KR, Gustafsson JA, Bernini F. “Pitavastatin effect on atp binding cassette a1-mediated lipid efflux from macrophages. Evidence for LXR-dependent and LXR-independent mechanisms of activation by cAMP”. J Pharmacol Exp Ther. 2006; 317(1): 1-7. Impact factor: 4,098

7. Duong M, Collins HL, Jin W, Zanotti I, Favari E, Rothblat GH. “Relative Contributions of ABCA1 and SR-BI to Cholesterol Efflux to Serum From Fibroblasts and Macrophages”. Arterioscler Thromb Vasc Biol. 2006 26(3):541-7. Impact factor: 7,053.

8. Favari E, Gomaraschi M, Zanotti I, Bernini F, Lee-Rueckert M, Kovanen PT, Sirtori CR, Franceschini G, Calabresi L. “A unique protease-sensitive HDL particle containing the apolipoprotein A-I Milano dimer effectively promotes ABCA1-mediated cell cholesterol efflux.” J Biol Chem. 2007; 282(8):5125-32. Impact factor: 5,854.

9. Ilaria Zanotti, Francesco Potì, Matteo Pedrelli, Elda Favari, Elsa Moleri, Guido Franceschini, Laura Calabresi, Franco Bernini. “The LXR agonist T0901317 promotes the reverse cholesterol transport from macrophages by increasing plasma efflux potential”. J. Lip. Res. 2008; 49(5):954-60. Impact factor: 4,409.

10. Pisciotta L, Bocchi L, Candini C, Sallo R, Zanotti I, Fasano T, Chakrapani A, Bates T, Bonardi R, Cantafora A, Ball S, Watts G, Bernini F, Calandra S, Bertolini S. “Severe HDL deficiency due to novel defects in the ABCA1 transporter”. J Intern Med. 2009 Mar;265(3):359-72. Impact factor: 5,412.

11. Ilaria Zanotti, Matteo Pedrelli, Francesco Potì, Grazia Stomeo, Monica Gomaraschi, Laura Calabresi, Franco Bernini. “Macrophage, but not systemic, apolipoprotein E is necessary for macrophage reverse cholesterol transport in vivo”. Arterioscler Thromb Vasc Biol. 2011; 31(1):74-80. Impact factor: 6,368.

12. Zanotti I, Maugeais C, Pedrelli M, Gomaraschi M, Salgam P, Calabresi L, Bernini F, Kempen H. “The thienotriazolodiazepine Ro 11-1464 increases plasma apoA-I and promotes reverse cholesterol transport in human apoA-I transgenic mice”. Br J Pharmacol. 2011; 164(6):1642-51. Impact factor: 4,409.

13. Ilaria Zanotti, Elda Favari, Franco Bernini. “Cellular cholesterol efflux pathways: Impact on Intracellular Lipid Trafficking and Methodological Considerations”. Curr Pharm Biot. 2012; 13(2):292-302. Impact factor: 2,805.

14. E. Favari, I. Zanotti, F.Bernini “Fenofibrato: aspetti terapeutici nelle dislipidemie”. Giornale italiano dell'arteriosclerosi 2012; 3: 49-62.

15. Ilaria Zanotti, Daniela Greco, Giulia Lusardi, Francesca Zimetti, Francesco Potì, Lorenzo Arnaboldi, Alberto Corsini, Franco Bernini “Cyclosporine A Impairs the Macrophage Reverse Cholesterol Transport in Mice by Reducing Sterol Fecal Excretion”. PlosOne 2013, 8(8):e71572. Impact factor: 3,534.

16. Sensi C, Simonelli S, Zanotti I, Tedeschi G, Lusardi G, Franceschini G, Calabresi L, Eberini I. “Distant homology modeling of LCAT and its validation through in silico targeting and in vitro and in vivo assays”. PLoS One. 2014 Apr 15;9(4):e95044. Impact factor: 3,234.

17. Tognolini M, Hassan-Mohamed I, Giorgio C, Zanotti I, Lodola A. “Therapeutic perspectives of Eph-ephrin system modulation.” Drug Discovery Today 2014. 19(5):661-9. Impact factor: 6.691

18. I Hassan-Mohamed, C Giorgio, M Incerti, S Russo, D Pala, E B Pasquale, P Vicini, I Zanotti, E Barocelli, S Rivara, M Mor, A Lodola, M Tognolini. “UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations”. Br J Pharmacol. 2014, 171(23):5195-208.. Impact factor:4.842

19. Pala D, Castelli R, Incerti M, Russo S, Tognolini M, Giorgio C, Hassan-Mohamed I, Zanotti I, Vacondio F, Rivara S, Mor M, Lodola A. “Combining Ligand- and Structure-Based Approaches for the Discovery of New Inhibitors of the EPHA2-ephrin-A1 Interaction.” J Chem Inf Model 2014. 54(10):2621-6. Impact factor: 3.738

20. Favari E, Chroni A, Tietge UJ, Zanotti I, Escolà-Gil JC, Bernini F. “Cholesterol Efflux and Reverse Cholesterol Transport.” Handb Exp Pharmacol. 2015;224:181-206

21. Zanotti I, Dall'Asta M, Mena P, Mele L, Bruni R, Ray S, Del Rio D. “Atheroprotective effects of (poly)phenols: a focus on cell cholesterol metabolism”. Food Funct. 2015 Jan 24;6(1):13-31. Impact factor: 2.686

22. Zanotti I, Turroni F, Piemontese A, Mancabelli L, Milani C, Viappiani A, Prevedini G, Sanchez B, Margolles A, Elviri L, Franco B, van Sinderen D, Ventura M. “Evidence for cholesterol-lowering activity by Bifidobacterium bifidum PRL2010 through gut microbiota modulation. Appl Microbiol Biotechnol. 2015 Aug;99(16):6813-29. Impact factor: 3.337
23. Castelli R, Tognolini M, Vacondio F, Incerti M, Pala D, Callegari D, Bertoni S, Giorgio C, Hassan-Mohamed I, Zanotti I, Bugatti A, Rusnati M, Festuccia C, Rivara S, Barocelli E, Mor M, Lodola A. “Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system”. Eur J Med Chem. 2015;103:312-324. Impact factor: 3.902
24. Piemontese A, Bernini F, Zanotti I. “Microbiota intestinale: un nuovo protagonista nella eziologia e nel trattamento dell’aterosclerosi?”. Giornale Italiano dell’Arteriosclerosi. 2016;7(4):64-83.
25. Mele L, Mena P, Piemontese A, Marino V, López-Gutiérrez N, Bernini F, Brighenti F, Zanotti I, Del Rio D. Antiatherogenic effects of ellagic acid and urolithins in vitro. Arch Biochem Biophys. 2016, 599:42-50. Impact factor: 3.165
26. Zimetti F, Caffarra P, Ronda N, Favari E, Adorni MP, Zanotti I, Bernini F, Barocco F, Spallazzi M, Galimberti D, Ricci C, Ruscica M, Corsini A, Ferri N. Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease. J Alzheimers Dis. 2016; 55(1): 315-320. Impact factor: 3.731
27. Maria Pia Adorni, Eleonora Cipollari, Elda Favari, Ilaria Zanotti, Francesca Zimetti, Alberto Corsini, Chiara Ricci, Franco Bernini and Nicola Ferri. Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages. Atherosclerosis 2016; 256:1-6. Impact factor: 4.239
28. Incerti M, Russo S, Callegari D, Pala D, Giorgio C, Zanotti I, Barocelli E, Vicini P, Vacondio F, Rivara S, Castelli R, Tognolini M, Lodola A. Metadynamics for Perspective Drug Design: Computationally Driven Synthesis of New Protein-Protein Interaction Inhibitors Targeting the EphA2 Receptor. J Med Chem. 2017. 60 (2), pp. 787-796. Impact factor: 6.253
29. Laura Mele, Stefania Carobbio, Nicoletta Brindani, Claudio Curti, Sergio Rodriguez-Cuenca, Guillaume Bidault, Pedro Mena, Ilaria Zanotti, Michele Vacca, Antonio Vidal-Puig, Daniele Del Rio.. Phenyl-γ-valerolactones, flavan-3-ol colonic metabolites, protect brown adipocytes from oxidative stress without affecting their differentiation or function. Molecular Nutrition and Food Research. 2017; 61(9). Impact factor: 5.151
30. Incerti, M., Russo, S., Callegari, D., Pala, D., Giorgio, C., Zanotti, I., Barocelli, E., Vicini, P., Vacondio, F., Rivara, S., Castelli, R., Tognolini, M., Lodola, A.”Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor” (2017) Journal of Medicinal Chemistry, 60 (2), pp. 787-796. Impact factor: 6.253
31. Daniele Del Rio, Francesca Zimetti, Paolo Caffarra, Michele Tassotti, Franco Bernini,
Furio Brighenti, Andrea Zini and Ilaria Zanotti. “The Gut Microbial Metabolite
Trimethylamine-N-Oxide Is Present in Human Cerebrospinal Fluid” (2017) Nutrients, 9(10). pii: E1053. Impact factor: 4.2.
32. Lodola A, Giorgio C, Incerti M, Zanotti I, Tognolini M. “Targeting Eph/ephrin system in cancer therapy.” Eur J Med Chem. 2017 Dec 15;142:152-162. Impact factor: 4.816
33. Ricci C, Ruscica M, Camera M, Rossetti L, Macchi C, Colciago A, Zanotti I, Lupo MG, Adorni MP, Cicero AFG, Fogacci F, Corsini A, Ferri N. “PCSK9 induces a pro-inflammatory response in macrophages.” Sci Rep. 2018 Feb 2;8(1):2267. Impact factor: 4.122.
34. Francesca Zimetti, Wladimir M. Freitas, Alessandra M. Campos, Mauricio Dahe2, Maria Pia Adorni, Franco Bernini, Andrei C. Sposito and Ilaria Zanotti. Cholesterol efflux capacity does not associate with coronary calcium, plaque vulnerability and telomere length in healthy octogenarians. J Lip Res 2018. 59(4):714-721. Impact factor: 4.51.
35. Camera M, Rossetti L, Barbieri SS, Zanotti I, Canciani B, Trabattoni D, Ruscica M, Tremoli E, Ferri N. PCSK9 as a Positive Modulator of Platelet Activation. J Am Coll Cardiol. 2018 Feb 27;71(8):952-954. Impact factor: 16.83.
36. Paolo Poggio, Paola Songia, Laura Cavallotti, Silvia S. Barbieri, Ilaria Zanotti, Benoît J. Arsenault, Vincenza Valerio, Nicola Ferri, Romain Capoulade and Marina Camera. PCSK9 involvement in aortic valve calcification. J Am Coll Cardiol. 2018. Accepted for publication. Impact factor: 16.83.
37. Anti-Atherosclerotic Effect of a Polyphenol-Rich Ingredient, Oleactiv®, in a Hypercholesterolemia-Induced Golden Syrian Hamster Model. Cindy Romain, Antonio Piemontese, Simone Battista, Franco Bernini, Alice Ossoli, Arianna Strazzella, Sylvie Gaillet, Jean-Max Rouanet, Julien Cases and Ilaria Zanotti. Nutrients 2018; 10(10). Impact factor: 4.2.

Total impact factor: 181.14
Mean impact factor: 5.32
H-index (scopus): 16

BOOKS
• Author of the chapter “Apparato cardiovascolare” (Cardiovascular system) in the book “Principi di Farmacognosia e Fitoterapia” (Principles of Pharmacognosy and Phytotherpay) by Uninova in 2007.

Dr Zanotti is a referee for the following journals:
• Pharmacological Research
• PlosOne
• Food & Function
• International Journal of Food Sciences & Nutrition
• Cholesterol
• Prostaglandins, Leukotrienes & Essential Fatty Acids
• Immunobiology
• Molecular Therapy
• Atherosclerosis
• Nutrients
• Phytomedicine
• Nutrition, metabolism and cardiovascular disease

Completion accademic year: 2020/2021

Completion accademic year: 2019/2020

Completion accademic year: 2013/2014

Professor/Teacher

Teacher tutor

Publications

Contacts

Phone number
905040